Skip to main content Accessibility help
×
Home

Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness

  • Ian M. Anderson and J. Guy Edwards

Extract

The selective serotonin reuptake inhibitors (SSRIs) are the most extensively studied of the newer antidepressants and are increasingly being used as first-line treatment for depression (Anderson et al, 2000). In this article we concentrate on issues that need to be taken into account when selecting one of the five SSRIs marketed in the UK (citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) for individual patients. We have concentrated on treatment of depression and have not reviewed their use in anxiety disorders because comparative data are lacking.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness
      Available formats
      ×

Copyright

References

Hide All
Anderson, I. M., Nutt, D. J. & Deakin, J. F. W. (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology Guidelines. Journal of Psychopharmacology, 14, 320.
Arias, F., Padin, J. J., Gilaberte, I. et al (1998) Comparative efficacy and tolerability among different selective serotonin re-uptake inhibitors and venlafaxine in a naturalistic setting. International Journal of Psychiatry in Clinical Practice, 2, 255260.
Borys, D. J., Setzer, S. C., Ling, L. J. et al (1992) Acute fluoxetine overdose: a report of 234 cases. American Journal of Emergency Medicine, 10, 115120.
Boyer, P., Danion, J. M., Bisserbe, J. C. et al (1998) Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics, 13, 157169
British Medical Association & Royal Pharmaceutical Society (2000) British National Formulary. London & Wallingford: British Medical Journal & Pharmaceutical Press.
Claxton, A. J., Chawla, A. J. & Kennedy, S. (1999) Absenteeism among employees treated for depression. Journal of Occupational and Environmental Medicine, 41, 605611.
Claxton, A. J., Li, Z. & McKendrick, J. (2000) Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. British Journal of Psychiatry, 177, 163168.
Dechant, K. L. & Clissold, S.P. (1991) Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs, 41, 225253.
Edwards, J. G. & Anderson, I. (1999) Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs, 57, 507533.
Edwards, J. G., Inman, W. H. W., Wilton, L. et al (1997) Drug safety monitoring of 12692 patients treated with fluoxetine. Human Psychopharmacology, 12, 127137.
Fava, M., Rosenbaum, J., Judge, R. et al (1998) Fluoxetine versus sertraline and paroxetine in major depression: long-term changes in weight. European Neuropsychopharmacology, 8 (Suppl. 2), S204.
Glassman, A. H. (1997) Citalopram toxicity. Lancet, 350, 818.
Goldstein, D. J. & Sundell, K. (1999) A review of the safety of selective serotonin reuptake inhibitors during pregnancy. Human Psychopharmacology, 14, 319324.
Goodnick, P. J. & Goldstein, B. J. (1998a) Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology. Journal of Psychopharmacology, 12, S5S20.
Goodnick, P. J. & Goldstein, B. J. (1998b) Selective serotonin reuptake inhibitors in affective disorders. II. Efficacy and quality of life. Journal of Psychopharmacology, 12, S21S54.
Gregor, K. J., Overhage, J. M., Coons, S. J. et al (1994) Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Clinical Therapeutics, 16, 306315.
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 5662.
Henry, J. A. (1991) Overdose and safety with fluvoxamine. International Clinical Psychopharmacology, 6 (Suppl. 3), 4145.
Henry, J. A., Alexander, C. A. & Sener, E. K. (1995) Relative mortality from overdose of antidepressants. British Medical Journal, 310, 221224.
Hylan, T. R., Dossenbach, M., Meneades, L. et al (1998) Antidepressant use in the psychiatrist setting in Austria: a comparison of citalopram, fluoxetine, and paroxetine. Journal of Serotonin Research, 4, 295303.
Hylan, T. R., Meneades, L., Crown, W. H. et al (1999) SSRI antidepressant use patterns and their relation to clinical global impression scores: a naturalistic study. Journal of Affective Disorders, 52, 111119.
Isacsson, G. & Bergman, U. (1996) Risks with citalopram in perspective. Lancet, 348, 1033.
Klein-Schwartz, W. & Anderson, B. (1996) Analysis of sertraline-only overdoses. American Journal of Emergency Medicine, 14, 456458.
Lawrenson, R. A., Tyrer, F., Newson, R. B. et al (2000) The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. Journal of Affective Disorders, 59, 149157.
Mackay, F. J., Dunn, N. R., Wilton, L.V. et al (1997) A comparison if fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiology and Drug Safety, 6, 235246.
Mackay, F. J., Dunn, N. R., Martin, R. M. et al (1999). Newer antidepressants: a comparison of tolerability in general practice. British Journal of General Practice, 48, 892896.
Michelson, D., Fava, M., Amsterdam, J. et al (2000) Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. British Journal of Psychiatry, 176, 363368.
Montejo-Gonzalez, A. L., Llorca, G., Izquierdo, J. A. et al (1997) SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of Sexual and Marital Therapy, 23, 176194.
Nemeroff, C. B., Ninan, P. T., Ballenger, J. et al (1995) Double-blind multicenter comparison of fluvoxamine verus sertraline in the treatment of depressed outpatients. Depression, 3, 163169.
Öström, M., Eriksson, A., Thorson, J. et al (1996) Fatal overdose with citalopram. Lancet, 348, 339340.
Personne, M., Sjoberg, G. & Persson, H. (1997) Citalopram overdose – review of cases treated in Swedish hospitals. Journal of Toxicology and Clinical Toxicology, 35, 237240.
Rosenbaum, J. F., Fava, M., Hoog, S. L. et al (1998) Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry, 44, 7787.
Russell, J. M., Berndt, E. R., Miceli, R. et al (1999) Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline. American Journal of Managed Care, 5, 597606.
Sclar, D. A., Robison, L. M., Skaer, T. L. et al (1995) Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. Journal of International Medical Research, 23, 395412.
Sclar, D. A., Skaer, T. L., Robison, L. M. et al (1999) Economic appraisal of citalopram in the management of single-episode depression. Journal of Clinical Psychopharmacology, 19, 47S54S.
Teicher, M. H., Glod, C. & Cole, J. O. (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 147, 207210.
Waldinger, M. D., Hengeveld, M. W., Zwinderman, A. H. et al (1998) Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. Journal of Clinical Psychopharmacology, 18, 274281.
Wilton, L. V., Pearce, G. L., Martin, R. M. et al (1998) The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. British Journal of Obstetrics and Gynaecology, 105, 882889.
Yoshida, K., Smith, B. & Kumar, R. C. (1999) Psychotropic drugs in mother's milk: a comprehensive review of assay methods, pharmacokinetics and of safety in breastfeeding. Journal of Psychopharmacology, 13, 6480.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness

  • Ian M. Anderson and J. Guy Edwards
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *